Scott Tobin Net Worth

The estimated Net Worth of Scott R Tobin is at least $163 Thousand dollars as of 12 October 2022. Mr. Tobin owns over 10,000 units of Champions Oncology Inc stock worth over $122,100 and over the last 11 years he sold CSBR stock worth over $0. In addition, he makes $41,020 as Independent Director at Champions Oncology Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Tobin CSBR stock SEC Form 4 insiders trading

Scott has made over 3 trades of the Champions Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CSBR stock worth $32,100 on 12 October 2022.

The largest trade he's ever made was exercising 10,000 units of Champions Oncology Inc stock on 12 October 2022 worth over $32,100. On average, Scott trades about 1,765 units every 42 days since 2013. As of 12 October 2022 he still owns at least 30,000 units of Champions Oncology Inc stock.

You can see the complete history of Mr. Tobin stock trades at the bottom of the page.

Scott Tobin biography

Scott R. Tobin serves as Independent Director of the Company. He served as a director of the Company since June 2011, pursuant to the terms of the Securities Purchase Agreement dated March 24, 2011 between the Company, Battery Ventures IX, L.P. (“BVIX”) and certain other investors and the Securities Purchase Agreement dated January 28, 2013 between the Company, BVIX and certain other investors, in which the Company agreed to appoint one nominee nominated by BVIX to become a member of the Company's Board. In 1997, Mr. Tobin joined Battery Partners IX, LLC, the general partner of BVIX, where he has been a managing member of various funds since May 2000. Prior to joining Battery Partners IX, LLC, Mr. Tobin held positions at First Albany Corp. and at Future Vision, a venture-backed software company that was sold to Softkey International. Mr. Tobin received a bachelor’s degree with honors in International Relations and Islamic and Middle Eastern Studies from Brandeis University in 1992.

What is the salary of Scott Tobin?

As the Independent Director of Champions Oncology Inc, the total compensation of Scott Tobin at Champions Oncology Inc is $41,020. There are 5 executives at Champions Oncology Inc getting paid more, with Ronnie Morris having the highest compensation of $1,343,650.

How old is Scott Tobin?

Scott Tobin is 49, he's been the Independent Director of Champions Oncology Inc since 2011. There are 9 older and no younger executives at Champions Oncology Inc. The oldest executive at Champions Oncology Inc is Abba Poliakoff, 68, who is the Independent Director.

What's Scott Tobin's mailing address?

Scott's mailing address filed with the SEC is C/O BATTERY VENTURES, ONE MARINA PARK DRIVE, SUITE 1100, BOSTON, MA, 02210.

Insiders trading at Champions Oncology Inc

Over the last 21 years, insiders at Champions Oncology Inc have traded over $9,072,751 worth of Champions Oncology Inc stock and bought 42,104,566 units worth $13,657,266 . The most active insiders traders include Ventures Ix, L.P.Battery In..., Michael Maurice Brown, and Sports Inc Champions. On average, Champions Oncology Inc executives and independent directors trade stock every 76 days with the average trade being worth of $2,196,294. The most recent stock trade was executed by Daniel Newman Mendelson on 12 January 2024, trading 1,000 units of CSBR stock currently worth $6,500.

What does Champions Oncology Inc do?

champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them

Complete history of Mr. Tobin stock trades at Champions Oncology Inc and Sprinklr

Champions Oncology Inc executives and stock owners

Champions Oncology Inc executives and other stock owners filed with the SEC include:

• Ronnie Morris,
  Chief Executive Officer, Director
• Dr. Ronnie Morris M.D.,
  Pres, CEO & Director
• David Miller,
  Chief Financial Officer
• David Barry Miller M.B.A.,
  Chief Financial Officer
• Joel Ackerman,
  Chairman of the Board
• Scott Tobin,
  Independent Director
• Abba Poliakoff,
  Independent Director
• Daniel Mendelson,
  Independent Director
• David Sidransky,
  Lead Independent Director
• Philip Breitfeld,
  Independent Director
• David DeOrnellis BS, CMAR, CPIA, RLATG,
  Exec. VP of Global Laboratory Operations
• Dr. Maria Mancini Ph.D.,
  Chief of Scientific Operations
• Dr. Michael Ritchie M.B.A., Ph.D.,
  Chief Commercial Officer
• Dr. Karin Abarca Heidemann,
  VP of Scientific Operations
• Ventures Ix, L.P.Battery In...,
  
• Michael Maurice Feldman Jes...,
  
• Ventures Ix, L.P.Battery In...,
  
• Arthur G Iii Epker,
  Director
• Michael Maurice Brown,
  10% owner
• James Martell,
  Chief Accounting Officer
• Ana Stancic,
  Director
• Douglas D Burkett,
  President
• Mark Schonau,
  Chief Financial Officer
• Durwood Settles,
  Director
• Sports Inc Champions,
  Chairman, President
• Enterprise Associates 14, L...,
  
• Brady Davis,
  President